Nicole Concin

List of Publications by Year
in descending order

65 papers	3,183 citations	257450 24 h-index	161849 54 g-index
66 all docs	66 docs citations	66 times ranked	3829 citing authors

#	Article	IF	Citations
1	Clear cell carcinoma of the endometrium. Gynecologic Oncology, 2022, 164, 658-666.	1.4	23
2	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0
3	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. Cancers, 2022, 14, 1780.	3.7	4
4	Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).. Journal of Clinical Oncology, 2022, 40, 5517-5517.	1.6	2
5	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
6	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. International Journal of Gynecological Cancer, 2021, 31, 713-720.	2.5	7
7	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99
8	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with) Tj ETQq0 0 0 rgBT /Overlock 10 Gynecological Cancer, 2021, 31, ijgc-2021-002668.	2.5	2
9	Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IBâ€"IIB cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 824-828.	2.5	6
10	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancerâ€"A Study of the OVCAD Consortium. Cancers, 2021, 13, 2613.	3.7	10
11	<scp>ESGO</scp>/<scp>ISUOG</scp>/<scp>IOTA</scp>/<scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2021, 58, 148-168.	1.7	42
12	BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer. Genes, 2021, 12, 969.	2.4	3
13	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 961-982.	2.5	54
14	Uterine serous carcinoma. Gynecologic Oncology, 2021, 162, 226-234.	1.4	58
15	Response to: Correspondence on "ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors" by Thomassin-Nagarra et al. International Journal of Gynecological Cancer, 2021, 31, 1396-1397.	2.5	1
16	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
17	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancerâ€"A Study of the OVCAD Consortium. Cancers, 2021, 13, 5865.	3.7	3
18	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13

#	Article	IF	Citations
19	Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecologic Oncology, 2020, 156, 308-314.	1.4	32
20	European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners – a new Model D for drug and medical device development. International Journal of Gynecological Cancer, 2020, 30, 730-734.	2.5	3
21	Definition and Independent Validation of a Proteomic-Classifier in Ovarian Cancer. Cancers, 2020, 12, 2519.	3.7	3
22	Implementing clinical practice guidelines: time to assess it. ESMO Open, 2020, 5, e001130.	4.5	0
23	ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncology, The, 2020, 21, e360-e368.	10.7	50
24	Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. International Journal of Gynecological Cancer, 2020, 30, 436-440.	2.5	61
25	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium. Frontiers in Oncology, 2019, 9, 832.	2.8	23
26	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
27	Fetal weight estimation at term – ultrasound versus clinical examination with Leopold's manoeuvres: a prospective blinded observational study. BMC Pregnancy and Childbirth, 2019, 19, 122.	2.4	15
28	Combining conventional therapy with immunotherapy: A risky business?. European Journal of Cancer, 2019, 113, 41-44.	2.8	25
29	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/-) platinum-sensitive ovarian cancer patients.. Journal of Clinical Oncology, 2019, 37, TPS5605-TPS5605.	1.6	0
30	AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer – a retrospective multi-centre study. BMC Cancer, 2018, 18, 447.	2.6	4
31	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients– A study of the OVCAD consortium. Gynecologic Oncology, 2018, 149, 371-380.	1.4	11
32	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. Analytical Chemistry, 2018, 90, 13273-13279.	6.5	18
33	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	1.4	44
34	Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival. Histopathology, 2018, 73, 1002-1012.	2.9	12
35	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2018, 36, 5567-5567.	1.6	5
36	Recommended Guidelines for Validation, Quality Control, and Reporting of <i>TP53</i> Variants in Clinical Practice. Cancer Research, 2017, 77, 1250-1260.	0.9	68

#	Article	IF	Citations
37	Use of Underarm Cosmetic Products in Relation to Risk of Breast Cancer: A Case-Control Study. EBioMedicine, 2017, 21, 79-85.	6.1	43
38	L1CAM in the Early Enteric and Urogenital System. Journal of Histochemistry and Cytochemistry, 2017, 65, 21-32.	2.5	9
39	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death and Differentiation, 2017, 24, 300-316.	11.2	16
40	The relative risk of second primary cancers in Austria's western states: a retrospective cohort study. BMC Cancer, 2017, 17, 699.	2.6	12
41	The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer – A Retrospective Study. PLoS ONE, 2017, 12, e0169272.	2.5	7
42	Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
43	Î³-Glutamyltransferase and Breast Cancer Risk Beyond Alcohol Consumption and Other Life Style Factors – A Pooled Cohort Analysis. PLoS ONE, 2016, 11, e0149122.	2.5	11
44	Jump in the fire – heat shock proteins and their impact on ovarian cancer therapy. Critical Reviews in Oncology/Hematology, 2016, 97, 152-156.	4.4	15
45	Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer, 2016, 16, 102.	2.6	68
46	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study. Tumor Biology, 2016, 37, 3009-3016.	1.8	23
47	Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2016, 34, e17038-e17038.	1.6	1
48	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. Anticancer Research, 2016, 36, 1015-22.	1.1	4
49	Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer. PLoS ONE, 2015, 10, e0125317.	2.5	40
50	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. Science of the Total Environment, 2015, 506-507, 644-655.	8.0	50
51	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. Journal of Clinical Oncology, 2015, 33, 5578-5578.	1.6	0
52	HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy, 2014, 7, 1563.	2.0	18
53	Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death and Differentiation, 2014, 21, 1240-1249.	11.2	29
54	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. Food and Chemical Toxicology, 2014, 72, 312-321.	3.6	77

#	Article	IF	Citations
55	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients â€" A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European Journal of Cancer, 2014, 50, 2090-2098.	2.8	75
56	The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer.. Journal of Clinical Oncology, 2013, 31, e16524-e16524.	1.6	0
57	Nomogram prediction for overall survival of patients diagnosed with cervical cancer.. Journal of Clinical Oncology, 2012, 30, 5111-5111.	1.6	0
58	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. Journal of Clinical Oncology, 2012, 30, 5071-5071.	1.6	1
59	Evidence for Cosmetics as a Source of Mineral Oil Contamination in Women. Journal of Women's Health, 2011, 20, 1713-1719.	3.3	27
60	Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene, 2011, 30, 4038-4049.	5.9	39
61	E2F3a Is Critically Involved in Epidermal Growth Factor Receptorâ€"Directed Proliferation in Ovarian Cancer. Cancer Research, 2010, 70, 4613-4623.	0.9	32
62	Primary chemotherapy and maintenance therapy in epithelial ovarian cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 99-102.	0.5	1
63	Mineral oil paraffins in human body fat and milk. Food and Chemical Toxicology, 2008, 46, 544-552.	3.6	72
64	Clinical Relevance of E2F Family Members in Ovarian Cancerâ€"An Evaluation in a Training Set of 77 Patients. Clinical Cancer Research, 2007, 13, 144-151.	7.0	103
65	Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo. Clinical Cancer Research, 2005, 11, 8372-8383.	7.0	89